UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of the latest pharma headlines in today's Pharmalittle newsletter.
UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of the latest pharma headlines in today's Pharmalittle newsletter.
<iframe src="https://statesidedaily.com/embed/cluster/049b90bfe6bc9620208436d721aa37ceef9d7fb9" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more"></iframe>
